Intertek Increases Biopharmaceutical Services Facility
Intertek has announced that it has expanded its center of excellence for biopharmaceutical services in Manchester, United Kingdom, to support the development of biologics and gene therapies.
Intertek has announced in an Oct. 29, 2019 press release that it has expanded its center of excellence for biopharmaceutical services in Manchester, United Kingdom, to support the development of biologics and gene therapies.
An additional 14,000 ft2 of laboratory space is currently being developed and will see the recruitment of more than 60 experts. The new facility is expected to be formally opened early on in 2020 and will include temperature-controlled laboratories and analytical technologies. The additional space will expand on the company’s current services, which include a broad range of good laboratory practice, good clinical laboratory practice, and good manufacturing practice bioanalysis and analysis services.
Ashleigh Wake, laboratory director, said in the press release, “As global demand grows for specialist contract laboratory services, particularly in the fields of biologics and gene therapy development, our latest expansion brings increased capacity and flexibility to help deliver solutions for our clients around the world enabling them to develop industry leading products adhering to evolving regulatory requirements.”
“We are delighted to expand and invest in our center of excellence for biopharmaceutical services in Manchester,” added Graham Ritchie, executive vice-president, Intertek Europe, in the press release. “The team has a strong heritage of supporting complex pharmaceutical product development through industry-leading analytical and regulatory expertise. This expansion advances our ability to help clients navigate the challenges of development programs for biologics or gene therapies through our systemic, end-to-end total quality assurance solutions.”
Source: Intertek
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
